摘要
目的观察尼莫地平联合神经节苷脂对急性脑出血患者的临床疗效及其对血清凝血酶敏感蛋白-1 (TSP-1)、C反应蛋白(CRP)、白细胞介素-8(IL-8)的影响。方法将86例急性脑出血患者随机分为对照组(n=46)和试验组(n=40)。对照组用尼莫地平治疗,每次4～8 mg,每天1次,微泵推注维持。试验组在对照组基础上给予神经节苷脂治疗,每次80 mg,每天1次,静脉滴注。2组均持续治疗14 d。比较2组患者的临床疗效、血清TSP-1、CRP、IL-8水平、血肿体积、神经功能缺损评分(NIHSS)、日常活动能力(ADL)评分和药物不良反应发生情况。结果治疗后,试验组和对照组总有效率分别为90. 00%(36例/40例)和71. 74%(33例/46例),差异有统计学意义(P <0. 05)。试验组和对照组血清TSP-1分别为(107. 49±11. 67)和(127. 19±15. 60)ng·m L^(-1),CRP分别为(3. 59±0. 52)和(5. 07±0. 56) mg·L^(-1),IL-8分别为(12. 31±1. 21)和(16. 04±2. 45) ng·L^(-1),血肿体积(5. 84±0. 54)和(9. 36±1. 35) m L,NIHSS分别为(9. 43±1. 07)和(12. 20±1. 50)分,ADL评分分别为(67. 78±8. 73)和(59. 09±8. 96)分,差异均有统计学意义(均P <0. 05)。2组药物不良反应均以急性肾损伤、消化道反应、皮疹为主,对照组和试验组的药物不良反应发生率分别为10. 87%和25. 00%,差异无统计学意义(P> 0. 05)。结论尼莫地平联合神经节苷脂对急性脑出血患者的疗效确切,可降低血清TSP1、CRP及IL-8水平,且未明显增加药物不良反应发生率。
Objective To analysis the clinical trial of nimodipine combined with ganglioside in treatment acute cerebral hemorrhage and its effect on serum thrombin serum protein-1(TSP-1),C-reactive protein(CRP)and interleukin-8(IL-8).Methods Eight-six cases of acute cerebral hemorrhage patients were randomly divided into control group(n = 46)and treatment group(n = 40).Control group was treated with nimodipine 4-8 mg,qd,micropump injection maintenance.Treatment group was treated with ganglioside 80 mg,qd,intravenous infusion on the basis of control group.Both groups were continuously treated for14 d.The clinical effect,serumLevels of TSP-1,CRP,IL-8,hematoma volume,National institute of health stroke scale(NIHSS),activity of daily living(ADL)and adverse drug reactions in two groups were compared.Results After treatment,the total effective rates in treatment group and control group were 90.00%(36cases/40 cases)and 71.74%(33 cases/46 cases),with significant difference(P<0.05).The serum TSP-1 in treatment group and control group were(107.49±11.67)and(127.19±15.60)ng·mL^-1,CRP were(3.59±0.52)and(5.07±0.56)mg·L^-1,IL-8 were(12.31±1.21)and(16.04±2.45)ng·L^-1,hematoma volume were(5.84±0.54)and(9.36±1.35)mL,NIHSS were 9.43±1.07 and 12.20±1.50,ADL scores were 67.78±8.73 and 59.09±8.96,all with significant difference(allP<0.05).The main adverse drug reactions in two groups were acute kidney injury,digestive tract reaction and skin rash.The incidence of adverse drug reactions in control group and treatment group were 10.87% and 25.00%,with no significant difference(P >0.05).Conclusion Nimodipine combined with ganglioside is effective in the treatment of acute cerebral hemorrhage,can reduce serumLevels of TSP-1,CRP and IL-8,and do not significantly increase the incidence of adverse drug reactions.
作者
罗建平
沈益金
吴爱祥
LUO Jian -ping;SHEN Yi -jin;WU Ai -xiang(Department of Clinical Laboratory,Ningbo Yinzhou People 's Hospital,Ningbo 315040,Zhejiang Province,China;Department of Neurosurgery,Ningbo Yinzhou People 's Hospital,Ningbo 315040,Zhejiang Province,China;Department of Pharmacy,Ningbo Yinzhou People 's Hospital,Ningbo 315040,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第1期6-9,共4页
The Chinese Journal of Clinical Pharmacology
基金
浙江省医药卫生基金资助项目(2011KYA065)
